397030 — AprilBio Co Share Price
Last trade - 00:00- KR₩366bn
- KR₩275bn
- KR₩28bn
- 56
- 29
- 28
- 28
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 31.34 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -30.25% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.03 | ||
| Price to Tang. Book | 4.05 | ||
| Price to Free Cashflow | 17.03 | ||
| Price to Sales | 13.31 | ||
| EV to EBITDA | 15.75 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 18.38% | ||
| Return on Equity | 26.9% | ||
| Operating Margin | 60.86% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | n/a | 23,395.94 | 200 | n/a | 27,514 | 17,000 | 33,000 | 183.59% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | -59.4 | +123.86 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AprilBio Co Ltd is a Korea-based company primarily engaged in the biological drug development business. The Company is primarily engaged in the bio-innovative new drug research and development (R&D) business such as antibody therapeutics and long-acting recombinant protein pharmaceuticals.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 30th, 2013
- Public Since
- July 28th, 2022
- No. of Shareholders
- 20,440
- No. of Employees
- 26
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 22,486,096
- Address
- 602, B Dong, CHUNCHEON, 24341
- Web
- http://www.aprilbio.com/
- Phone
- +82 269568383
- Auditors
- BDO Sunghyun LLC
Upcoming Events for 397030
Similar to 397030
3Billion
Korea Exchange - KOSDAQ
ABion
Korea Exchange - KOSDAQ
ABL Bio
Korea Exchange - KOSDAQ
Amicogen
Korea Exchange - KOSDAQ
AptaBio Therapeutics
Korea Exchange - KOSDAQ
FAQ
As of Today at 19:17 UTC, shares in AprilBio Co are trading at KR₩16,290. This share price information is delayed by 15 minutes.
Shares in AprilBio Co last closed at KR₩16,290 and the price had moved by +8.6% over the past 365 days. In terms of relative price strength the AprilBio Co share price has outperformed the FTSE Developed Asia Pacific Index by +9.84% over the past year.
The overall consensus recommendation for AprilBio Co is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreAprilBio Co does not currently pay a dividend.
AprilBio Co does not currently pay a dividend.
AprilBio Co does not currently pay a dividend.
To buy shares in AprilBio Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩16,290, shares in AprilBio Co had a market capitalisation of KR₩366bn.
Here are the trading details for AprilBio Co:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 397030
Based on an overall assessment of its quality, value and momentum AprilBio Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in AprilBio Co is KR₩35,000. That is 114.86% above the last closing price of KR₩16,290.
Analysts covering AprilBio Co currently have a consensus Earnings Per Share (EPS) forecast of KR₩373 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AprilBio Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -21.36%.
As of the last closing price of KR₩16,290, shares in AprilBio Co were trading -11.01% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The AprilBio Co PE ratio based on its reported earnings over the past 12 months is 31.34. The shares last closed at KR₩16,290.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on AprilBio Co's directors